Desde 500€ puedes invertir en Biocross a través de Blockchain
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
Will Spain put an end to Alzheimer’s?
Early diagnosis of this disease is one of the factors that would enable better treatment. This is a key focus of many of the biotechnology companies that have emerged in recent decades.
CTAD 2014 presentation of a blood-based 7-metabolite signature for the early diagnosis of Alzheimer´s disease.
Biocross S.L., an innovative developer of assays for risk assessment and prediction of AD, has announced that it will be presenting a poster at the Clinical Trials on Alzheimer’s disease Conference, CTAD 2014, Philadelphia, United States, November 20-22nd, discussing its blood-based 7-metabolite signature for the early diagnosis of Alzheimer’s disease.
Biocross is involved in a new clinical study
The company recently completed a multicenter exploratory study in which seven Spanish hospitals participated, to identify markers of the disease. The study involved 306 patients.
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96